子宮頸がん委員会

1. Toita T, Kato S, Ishikura S, Tsujino K, Kodaira T, Uno T, Hatano K, Sakurai H, Niibe Y, Kazumoto T, Nishimura T, Kitagawa R, Fukutani M, Oguchi M, Umayahara K, Hirashima Y, Aoki Y, Takizawa K; and Disease Committee of Radiation Oncology, Japanese Gynecologic Oncology Group.
   Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer.
   Int J Clin Oncol. 2011; 16 : 379-86.
   
2. Yamamoto K, Kokawa K, Umesaki N, Nishimura R, Hasegawa K, Konishi I, Saji F, Nishida M, Noguchi H, Takizawa K.
   Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study.
   Oncol Rep. 2009 Apr;21(4):1005-9.
   
3. Kokawa,K., Umesaki,N., Yamamoto,K., Takizawa, K., Konishi, I., Hasegawa,K.,;
   Phase I study of irinotecan combined with mitomycin- C and 5-fluorouracil for gynecological malignancies;
   The JGOG Study. Anticancer Research 28;2933-2939 (2008)
   
4. Yamamoto K, Izumi R, Hasegawa K, Nakajima H, Ohashi K, Kudo R, Okuda H, Takahashi T, Origasa H, Sugimori H. Adjuvant oral 5-fluorouracil for cervical cancer: Japanese Gynecologic Oncology Group report. Int J Oncol. 2004 May;24(5):1175-9
   
5. Umesaki N, Fujii T, Nishimura R, Tanaka T, Nishida M, Fushiki H, Takizawa K, Yamamoto K, Hasegawa K, Izumi R; Japan Gynecologic Oncology Group. Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study. Gynecol Oncol. 2004 Oct;95(1):127-32.
   
6. 梅咲直彦、野口浩、伏木弘、西田正人、奥田博之、滝澤憲、宇田川康博、山本嘉一郎、長谷川和男、泉陸一．進行・再発子宮頸癌に対するBOMP療法の効果（子宮頸がん第5次特定研究DS-1）．第18回婦人科がん化学療法共同研究会記録集 23-27, 2001
   
7. 梅咲直彦、泉陸一、宇田川康博、奥田博之、河野一郎、杉森甫、滝澤憲、西田正人、 長谷川和男、伏木弘、山本嘉一郎、野田起一郎、田中哲二．進行および再発子宮頸部腺癌に対するMEP療法の効果．Oncol Chemother.182-186, 2000
   
8. Umesaki N, Izumi R, Fushiki H, Hasegawa K, Kono I, Nishida M, Noguchi H, Okuda H, Sugimori H, Takizawa K, Udagawa Y, Yamamoto K, Tanaka T, Noda K. Cervical adenocarcinoma, a novel combination chemotherapy with mitomycin C, etoposide, and cisplatin for advanced or recurrent disease. Gynecol Oncol.1999 Oct;75(1):142-4.
   

子宮体がん委員会

1. H. Nomura, D. Aoki, F. Takahashi, N. Katsumata, Y. Watanabe, I. Konishi, T. Jobo, M. Hatae, M. Hiura, N. Yaegashi, Japanese Gynecologic Oncology Group
   Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).
   Annals of Oncology 2011: 22: 636-642
   
2. Watanabe Y, Kitagawa R, Aoki D, Takeuchi S, Sagae S, Sakuragi N, Yaegashi N;
   Disease Committee of Uterine Endometrial Cancer, Japanese Gynecologic Oncology Group.
   Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese Gynecologic Oncology Group(JGOG2044s).
   Gynecol Oncol. 2009 Dec;115(3):456-9.
   
3. Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, Kudo R;
   Japanese Gynecologic Oncology Group.
   Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
   Gynecol Oncol. 2008 Jan;108(1):226-33.
   
4. Watanabe Y, Aoki D, Kitagawa R, Takeuchi S, Sagae S, Sakuragi N, Yaegashi N;
   Disease Committee of Uterine Endometrial Cancer, Japanese Gynecologic Oncology Group.
   Status of surgical treatment procedures for endometrial cancer in Japan: results of a Japanese Gynecologic Oncology Group survey.（JGOG2045s）
   Gynecol Oncol. 2007 May;105(2):325-8.
   
5. 佐藤信二、野澤志朗、宇田川康博、丹羽憲司、寒河江悟、工藤隆一、蔵本博行、西谷巖．子宮体がん化学療法第三次研究の最終解析成績．第17回婦人科がん化学療法共同研究会記録集22-27,2000
   
6. 佐藤信二、矢嶋聰、野澤志朗、宇田川康博、寺島芳輝、西谷巖、小澤満、工藤隆一、蔵本博行、岡田弘二．子宮体がん化学療法第2次研究の最終解析成績．Oncol Chemother.12(Suppl)：14-20,1996
   
7. 佐藤信二、矢嶋聰、野澤志朗、宇田川康博、寺島芳輝、西谷巖、小澤満、工藤隆一、蔵本博行、 岡田弘二．　子宮体癌に対する補助化学療法および寛解導入療法　子宮体がん化学療法第一次研究．Oncol Chemother. 11(3)：188-197,1995
   

卵巣がん委員会

1. Ushijima K, Kamura T, Tamura K, Kuzuya K, Sugiyama T, Noda K, Ochiai K.
   Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
   Int J Clin Oncol. 2011 Nov 30.
   
2. Takakura S, Takano M, Takahashi F, Saito T, Aoki D, Inaba N, Noda K, Sugiyama T, Ochiai K; Japanese Gynecologic Oncology Group.
   Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
   Int J Gynecol Cancer. 2010; 20: 240-7.
   
3. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K; Japanese Gynecologic Oncology Group.
   Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
   Lancet. 2009 Oct 17;374(9698):1331-8.
   
4. Hatae M, Onishi Y, Noda K, Yakushiji M, Ozaki K, Ochiai K, Kuzuya K, Takahashi T, Tateno M, Yoshikawa H, Nishida T.
   RANDOMIZED TRIAL ON ADJUVANT IV CHEMOTHERAPY CDDP + CPA VERSUS PO CHEMOTHERAPY CPA FOR STAGE IA OVARIAN CANCER BY THE JAPANESE GYNECOLOGIC ONCOLOGY AND CHEMOTHERAPY STUDY GROUP (Meeting abstract). 1998 ASCO Annual Meeting Abstract No: 1412